US Oncologist Survey: Optimizing Treatment for Large Cell Lymphoma


April 22, 2011
35 Pages - SKU: TAG3806091
License type:
Table of Contents Search inside this report Related Reports
Countries covered: United States

Two patient specific case scenarios on advanced non-Hodgkin’s lymphoma involving patients with a) relapsed large cell lymphoma and b) large cell lymphoma with compromised cardiac function that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progressions reveal:
  • Decisions in treatment and tests through disease stages
  • Factors influencing their decisions
  • Barriers to optimal patient care
  • Confidence in treatment
Data has been synthesized to show all responses and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on advanced non-Hodgkin’s lymphoma.

Treatment decisions for advanced stages of cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.

This report allows you to:
  • Understand what occurs with actual patients
  • Access the most up-to-date prescribing trends
  • Gain actionable data for developing and improving your market strategies
  • Pinpoint needs of your target audience
  • Focus resources to maximize the effectiveness of your budget
  • Understand where your product fits
  • Understand where your competitor’s product fits
  • Design messages to advance brand performance


Additional Information

Report Excerpt

Non-Hodgkin’s lymphoma (NHL) refers to a type of cancer that originates in the lymphatic system, including the lymph nodes, spleen, and other organs of the immune system. Most non-Hodgkin’s lymphomas develop from a type of white blood cell called B lymphocytes, or B cells. NHLs are estimated to be the 6th most common type of cancer in the United States.

Radiation therapy may be used for disease that is confined to one body area, and radioimmunotherapy may be used in some cases. Chemotherapy is commonly used as the main form of treatment. Most often, multiple different drugs are used in combination. People with lymphoma that returns after treatment or does not respond to treatment may receive high-dose chemotherapy followed by an autologous bone marrow transplant.
Executive Summary
Chapter 1: Introduction
Table 1. Treatment Options in Non-Hodgkin’s Lymphoma
Chapter 2: Respondent Demographics
Table 2. Eligibility Criteria for Survey Participation
Figure 2.1 Gender of Survey Respondents
Figure 2.2 Years since Medical School Graduation
Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers
Figure 2.5 Geographic Settings
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.6 Survey Respondents by State’s Non-Hodgkin’s Lymphoma Mortality
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen
Chapter 3: Patient with Relapsed Large Cell Lymphoma
Figure 3.1 Barriers to optimal care of large cell lymphoma
Figure 3.2 Confidence in treatment
Figure 3.3 First line treatment approach to patient with large cell lymphoma
Figure 3.4 Factors that influence treatment decision
Figure 3.5 Preferred R-CHOP regimen
Figure 3.6 Next step in management following R-CHOP
Figure 3.7 Treatment for progressing B-cell large cell lymphoma
Figure 3.8 Factors influencing treatment decision
Figure 3.9 Treatment following response then relapse from second-line therapy
Chapter 4: Patient with Large Cell Lymphoma with Compromised Cardiac Function
Figure 4.1 Confidence in treatment for large cell lymphoma with compromised cardiac function
Figure 4.2 Treatment approach for large cell lymphoma with compromised cardiac function
Figure 4.3 Factors influencing treatment of large cell lymphoma with compromised cardiac function
Figure 4.4 Treatment approach for large cell lymphoma with compromised cardiac function
Figure 4.5 Second-line treatment for large cell lymphoma with compromised cardiac function
Chapter 5: Summary
Appendix A: Survey Instrument

More Oncology/Hematology reports by The Assessment Group

US Market Changes in the Treatment of Advanced Melanoma by The Assessment Group
Progressively unfolding patient case scenarios were presented to 200 U.S. oncologists, who manage patients with advanced melanoma, to understand differences in clinical decisions and the ...
US Market Changes in the Treatment of Non-Hodgkin's Lymphoma by The Assessment Group
The purpose of this research study is to examine the current and evolving practice patterns of oncologists in managing advanced non-Hodgkin’s lymphoma. A survey ...
US Market Changes in the Treatment of Advanced Prostate Cancer by The Assessment Group
Progressively unfolding patient case scenarios were presented to 151 U.S. oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. ...
US Market Changes in the Treatment of Advanced Lung Cancer by The Assessment Group
The purpose of this study is to examine changes in the market for therapeutics used in the treatment of advanced lung cancer by examining longitudinal ...
See all reports like this >>

More United States Oncology/Hematology reports

US Cancer Diagnostics Market: Innovative Technologies and Emerging Business Opportunities by Venture Planning Group
This report contains 620 pages, 103 tables and presents a comprehensive analysis of the US cancer diagnostics market, including: Major issues pertaining to the US laboratory ...
US Proton Therapy Market Analysis to 2017 by RNCOS
According to most Oncologists, about 60% of all cancer patients undergo some sort of radiation therapy during their course of treatment. Despite advances in technology ...
United States Oncology Drug Delivery Preferences and Opportunities in Cancer Drug Delivery by Frost & Sullivan
Drug delivery is an important area of drug development in the pharmaceutical and biotechnology industry. In Oncology, developers are interested in understanding the opportunities and ...
The US Hematology Market: Instrument and Consumable Sales Forecasts by Market Segment, Key Supplier Shares by Venture Planning Group
This report provides an overview of the US hematology market, including sales and market shares of leading instrument and consumable suppliers, as well as test ...
See all reports like this >>

More United States reports

D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: The United States of America by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Country Report United States January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
Coal - US - a snapshot (2010) by Mintel - Snapshots
Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...
See all reports like this >>

 

Research assistance

We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 

Related Markets


Oncology/Hematology Reports

 
 

Share this report


Other tasks

 
 

Join Alert Me now!

Receive bi-weekly email alerts on new market research

Sign up today!